USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: PHYSIOGENIX, INC.
City: WAUWATOSA
State: WI
Zip+4: 53226-4838
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $3,640,066.00 7
SBIR Phase II $1,510,588.00 2

Award List:

DESIGNER RAT MODELS THAT MIMIC TYPE 2 DIABETES

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Steven H. Nye
Award Amount: $489,659.00
Abstract:
This SBIR Phase I project will employ a new bioinformatic tool to combine in silico gene mapping and comparative genomics for predicting designer rat strains that mimic human disease. The genome sequencing projects are bringing new molecular tools to both the pharmacologist and toxicologist. … More

COMBINATORIAL RAT PANELS FOR PHARMACOGENETIC EFFECTS

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Steven H. Nye
Award Amount: $100,000.00
Abstract:
This SBIR Phase I project will create and validate a combinatorial panel of rats designed to detect genetic differences to drug response including toxicity. The genome sequencing projects are bringing new molecular tools to both the pharmacologist and toxicologist. However, each species has its own… More

Combinatorial rat panels that genetically screen anthrax

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Steven H. Nye
Award Amount: $312,536.00
Abstract:
DESCRIPTION (provided by applicant): The recent anthrax-related events have revealed the need to fill gaps in the knowledge base that compromise our response to a bioterrorist attack using Category A pathogens like Bacillus anthracis. As with most biological systems, there is tremendous diversity… More

Combinatorial rat panels for pharmacogenetic effects

Award Year / Program / Phase: 2004 / SBIR / Phase II
Agency: HHS
Principal Investigator: Steven H. Nye
Award Amount: $134,425.00
Abstract:
DESCRIPTION (provided by applicant): The concept of a pre-clinical, drug screen for genetic effects was developed by PhysioGenix in Phase I of this project. The screen consists of inbred rats bred in a combinatorial fashion such that F1 offspring mimic the genetically diverse human population, while… More

Identifying drug toxicity signatures using QCarrays

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Steven H. Nye
Award Amount: $498,610.00
Abstract:
DESCRIPTION (provided by applicant): This Phase I SBIR project uses a new Quality Control microarray (QCarray) technology to generate Drug Toxicity Signatures (DTSs) for predicting liver toxicity in rat. The QCarray enables each element on every array to have a quality control (QC) score and… More

Consomic rat panels for pharmacogenomic studies and target identification

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Steven H. Nye
Award Amount: $1,644,226.00
Abstract:
DESCRIPTION (provided by applicant): PhysioGenix plans to commercialize a rat discovery platform that markedly accelerates the deployment of genetic tools for drug development by Pharma. While genetics can offer pharmaceutical companies a powerful discovery tool, this strategy has not been widely… More

Molecular fingerprints of alcohol-induced organ damage using new genetic models

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Steven H. Nye
Award Amount: $251,239.00
Abstract:
DESCRIPTION (provided by applicant): This SBIR project combines the use of genetic models with genomic, proteomic and metabolomic technologies as a solution to discover molecular fingerprints as biomarkers for alcohol-induced organ damage. While several classic biomarkers have been used by… More

Consomic rat panels for pharmacogenomic studies and target identification

Award Year / Program / Phase: 2007 / SBIR / Phase II
Agency: HHS
Principal Investigator: Steven H. Nye
Award Amount: $1,376,163.00
Abstract:
Not avaiable.

Efficacy of GABAA a5 receptor inverse agonists in learning impaired rats

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Earl M. Gibbs
Award Amount: $343,796.00
Abstract:
DESCRIPTION (provided by applicant): The number of patients in the United States afflicted with learning and memory disorders is rapidly increasing. This necessitates the development of new, better acting and safer medications for enhancing cognition. In this SBIR Phase I project, PhysioGenix will… More